RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Lineage Cell Therapeutics Stock

Lineage Cell Therapeutics Debt 2024

Lineage Cell Therapeutics Debt

-35.3 USD

Ticker

LCTX

ISIN

US53566P1093

WKN

A2PP89

In 2024, Lineage Cell Therapeutics's total debt was -35.3 USD, a 212.38% change from the -11.3 USD total debt recorded in the previous year.

Lineage Cell Therapeutics Aktienanalyse

What does Lineage Cell Therapeutics do?

Lineage Cell Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of cell therapies for various diseases. Originally established in 1990 as VisiGenics Inc., specializing in proteomic and genetic analysis, the company later changed its name to Lineage Cell Therapeutics Inc. to reflect its focus on the research and development of stem cell therapies. Lineage Cell Therapeutics develops and markets cell therapy products based on its own patents and discoveries, including therapies for eye, neurodegenerative, and cancer diseases. The company's proprietary technology platform gives it a crucial position in the field of cell therapy. Additionally, Lineage Cell Therapeutics collaborates with academic institutions and other biopharmaceutical companies to expedite the process of commercializing cell therapies. The company offers a wide range of cell therapies for various injuries and diseases, with key applications including: - OPC1: A cell-based therapy for spinal cord injuries caused by damage to the spinal cord. This therapy is being developed on the astrocyte differentiation treatment platform derived from embryonic stem cells (ES cells). - OpRegen: A cell-based regenerative product for dry age-related macular degeneration (tAMD). This therapy is based on the retinal pigment epithelium cell differentiation treatment platform derived from human embryonic stem cells. - VAC: An immunotherapy for cancer treatment. This treatment involves dendritic cells isolated from the patient's blood and genetically modified to present cancer-specific antigens. The goal is to stimulate the patient's immune system to trigger a specific immune response against cancer. Lineage Cell Therapeutics also pursues a strong expansion strategy. In 2020, it acquired a majority stake in AgeX Therapeutics, a biotechnology company focused on developing innovations in the field of stem cells. This acquisition strengthened the company's capacity for innovation and increased its ability to capitalize on future growth opportunities through partnerships, licensing, and product launches. Overall, Lineage Cell Therapeutics has become a significant player in the field of cell therapy, thanks to the use of cutting-edge technology and years of experience in the life science industry. One of the company's main goals is to develop and manufacture groundbreaking cell therapies to ultimately improve the lives of patients worldwide. Lineage Cell Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Lineage Cell Therapeutics's Debt Structure

Lineage Cell Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Lineage Cell Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Lineage Cell Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Lineage Cell Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Lineage Cell Therapeutics stock

What is the debt of Lineage Cell Therapeutics this year?

Lineage Cell Therapeutics has a debt level of -35.3 USD this year.

What was the debt of Lineage Cell Therapeutics compared to the previous year?

The debt of Lineage Cell Therapeutics has increased by 212.38% compared to the previous year increased.

What are the consequences of high debt for investors in Lineage Cell Therapeutics?

High debt can pose a risk for investors of Lineage Cell Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Lineage Cell Therapeutics?

Low debt means that Lineage Cell Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Lineage Cell Therapeutics affect the company?

An increase in debt of Lineage Cell Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Lineage Cell Therapeutics affect the company?

A reduction in debt of Lineage Cell Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Lineage Cell Therapeutics?

Some factors that can influence the debt of Lineage Cell Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Lineage Cell Therapeutics so important for investors?

The debts of Lineage Cell Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Lineage Cell Therapeutics take to change the debt?

To change the debt, Lineage Cell Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Lineage Cell Therapeutics pay?

Over the past 12 months, Lineage Cell Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Lineage Cell Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Lineage Cell Therapeutics?

The current dividend yield of Lineage Cell Therapeutics is .

When does Lineage Cell Therapeutics pay dividends?

Lineage Cell Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Lineage Cell Therapeutics?

Lineage Cell Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Lineage Cell Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Lineage Cell Therapeutics located?

Lineage Cell Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Lineage Cell Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Lineage Cell Therapeutics from 10/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/12/2024.

When did Lineage Cell Therapeutics pay the last dividend?

The last dividend was paid out on 10/12/2024.

What was the dividend of Lineage Cell Therapeutics in the year 2023?

In the year 2023, Lineage Cell Therapeutics distributed 0 USD as dividends.

In which currency does Lineage Cell Therapeutics pay out the dividend?

The dividends of Lineage Cell Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Lineage Cell Therapeutics

Our stock analysis for Lineage Cell Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lineage Cell Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.